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pidemiology involves the observation of health
states within a general population context.In the case of
mild cognitive impairment (MCI), this is important in
that we are dealing with what is essentially a subclinical
state,ie,a health problem that is likely to remain unre-
ported to a health professional for an extended period of
time,and for which the most common first point of con-
tact will be the general practitioner.It is also a heteroge-
neous entity:subclinical cognitive disorder has multiple
interacting causes, as illustrated in Figure 1.While the
concept of MCI has progressively been narrowed down
to a subgroup of persons in the first stages of a probable
neurodegenerative process,this group will nonetheless
be subject to many of the other causes of cognitive
decline,which will interact with the disease process and
complicate the definition and screening of MCI.General
population studies of a disorder allow us to see the full
range of cases within a naturalistic setting,which includes
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Mild cognitive impairment (MCI) refers to cognitive impairment that is assumed to be due to pathological central ner-
vous system processes, but which interacts with normal aging-related changes. Epidemiological studies conducted in
the general population have been able to examine more heterogeneous forms of this disorder than clinical studies,
and have also been able to provide early estimations of population incidence and prevalence. Large differences in case
identification procedures and sampling methods have led to considerable divergence in the rates of prevalence
reported, which ranged from 1% to 29%. Suggested improvements in the definition of MCI have led to an upward
adjustment of prevalence rates in most studies, giving between 5% and 29%. Incidence is estimated as 8 to 58 new
cases per thousand persons per year, and the probability of conversion from MCI to dementia is estimated at around
15%. The principal risk factors that have been identified so far for MCI using regression models applied to general
population data are age, education, race, medicated hypertension, infarcts, white matter lesions, depression, and
apolipoprotein E4 (APOE-4) allele. An etiological model derived from these studies indicates possible intervention
points for future therapeutic strategies at the level of both clinical intervention and environmental exposure. There
is, however, a clear need for epidemiological studies that take into account a broader range of risk factors than those
studied to date, which have focused principally on known risk factors for dementia.  
© 2004, LLS SAS Dialogues Clin Neurosci. 2004;6:401-408.a wide range of potential risk factors.Longitudinal obser-
vation of a general population sample with subclinical
cognitive deficits has demonstrated multiple patterns of
cognitive change with variable clinical outcomes includ-
ing dementia,depression,cardiovascular disease,and res-
piratory disorders.
1 However,the identification of those
cases likely to evolve towards dementia has been given
priority,especially given the development of treatments
that may delay dementia onset.The potential treatment
window for dementia is large,with twin studies indicat-
ing that insidious changes in cognitive performance may
occur up to 20 years before disease onset.
2 Population
studies allow us to develop models of disease etiology
within this more complex multifactor setting.
Epidemiology has a triple role in terms of public health:
• Descriptive epidemiology: the monitoring of disease
prevalence and incidence across time.
• Analytical epidemiology:the determination of risk fac-
tors and their patterns of interaction, permitting the
construction of hypothetical etiological models of dis-
ease processes.
• Interventional epidemiology:the designation of poten-
tial intervention points for the reduction of morbidity
and mortality,which may guide more targeted clinical
research.
MCI will be discussed here in relation to these three
functions.
Descriptive epidemiology of MCI
The emergence of MCI as a health problem and the
expansion of cognitive morbidity at a population level are
clearly related to the general phenomenon of population
aging.As Gruenberg
3 pointed out in 1977,it is one of the
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Figure 1. Mild cognitive impairment has multiple interacting causes. CNS, central nervous system.
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Cohort effects: expectations of what is 
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Genetic mechanisms, including genetic 
predisposition, and aging-related 
effects on mitotic regulation“failures of success” that, while medical research has
reduced the mortality of disease, it has concurrently
extended life expectancy and increased the proportion of
persons in the community with chronic pathologies.
Analyses of longitudinal health survey data from the USA
by Kramer
4 in the early 1980s provided early empirical evi-
dence of the rapid expansion of dependency due to cog-
nitive disorders arising from increases in disease incidence,
better management of its physiological consequences,and
thus decreased direct mortality.This public health dilemma
was,in fact,predicted by Jonathan Swift in the early 18th
century.In Gulliver’s Travels,
5 he described the cognitive
consequences of extended longevity in eternal beings,who,
on reaching the age of 80 and in the absence of degenera-
tive disease,continue to perform daily activities but have
difficulty in recalling the names of common objects and
recently read material,forget the name of friends,and con-
sequently have diminished pleasure in life.It is a descrip-
tion that comes quite close to current definitions of MCI,
and distinguishes MCI from normal aging and dementia.
Referring to the latter,whom he describes as “those who
turn to dotage,”he suggests that they may be more fortu-
nate in that they elicit pity rather than ridicule.
The extent to which MCI may be a disabling process is
largely unknown because the usual definition proposed by
Petersen and colleagues,
6,7 and adopted by most
researchers in this area,stipulated that MCI is a state that
does not interfere with everyday activities.More recently,
this definition has been relaxed to include the possibility
that MCI may impede, but not prevent, everyday func-
tioning.On this basis,it has subsequently been shown that
MCI may be associated with increasing difficulties in the
performance of a wide range of everyday tasks,notably
dressing,dental care,and the use of a telephone.
8We do
not know, on the other hand, to what extent MCI may
indirectly lead to activity restriction due to,for example,
withdrawal from a social activity due to fear of being
embarrassed by a memory problem. Little is currently
known either about the extent to which MCI may influ-
ence mortality rates.While dementia has been clearly asso-
ciated with increased mortality with a life expectancy on
average of 8 years from the time of diagnosis,the impact
of MCI on survival remains unclear.Cumulative mortal-
ity risk in MCI has been estimated by Gussekloo et al
9
using a Cox proportional hazards model with a cohort of
891 subjects from the Leiden Aging Study.Compared with
normal subjects the cumulative risk was found to be 2.5.
The study is however, limited by its use of the Mini-
Mental-State Examination (MMSE)
10 to define MCI.
How widespread is MCI in the general population?
Establishing the prevalence and incidence of MCI has
above all been hindered by the lack of an operational def-
inition of the disorder adapted to general population use,
where case selection cannot normally be based on a com-
plete neurological examination.Early conceptualizations
of subclinical cognitive deficit were based on the theoret-
ical assumption that such changes are distinct from demen-
tia and other pathologies, being the consequence of
inevitable aging-related cerebral changes,such as cortical
atrophy,which may be considered a normal feature of the
aging process. As parallel research into the causes of
dementia and cerebrovascular disease has now led to a
clearer understanding of their etiology, it has also been
shown that many of the physiological abnormalities seen
in these disorders are also present to a lesser extent in nor-
mal subjects with cognitive complaints,but these factors
cannot currently be incorporated into diagnostic criteria
due to difficulties in establishing precise universal cutoff
points between MCI and normal subjects.The diagnostic
criteria for MCI proposed by Petersen et al
6 thus refer to
complaints of defective memory and demonstration of
abnormal memory functioning for age,which may be more
easily quantified by reference to standard deviation from
scores obtained by normal elderly subjects.The remaining
criteria are principally exclusion criteria:normal general
cognitive functioning and conserved ability to perform
activities of daily living.MCI is considered above all to be
a prodrome of Alzheimer’s disease and,variably,of other
dementias.MCI criteria refer to poor cognitive function-
ing as assessed at one point in time, thus precluding an
appreciation of decline over time;it is thus difficult to dif-
ferentiate from cohort effects,low IQ,and education.Later
definitions by Petersen et al
7 refined the initial concept by
referring to memory impairment beyond that expected for
both age and education level.This has been the working
definition adopted by most epidemiological studies.
The definition of MCI has been developed within a clini-
cal setting.As such,the definition represents a minimal set
of distinguishing criteria,the diagnosis resting largely on
the overall clinical picture.Validation of the criteria has
been in terms of their capacity to predict conversion to
dementia and/or Alzheimer’s disease.The two are often
used interchangeably,which has led to some confusion in
the comparison of results across centers.Table I
7,11-18 shows
the predictive value of MCI criteria within a clinical set-
ting.Conversion rates to dementia are also noted for some
Epidemiology of mild cognitive impairment - Ritchie Dialogues in Clinical Neuroscience - Vol 6 . No.4 . 2004
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ical samples is reported at between 10% and 20%,regard-
less of age.Together,these studies suggest the predictive
validity of the concept within a clinical setting.
These studies are all,however,based on clinical series con-
ducted in specialist centers, so it is not certain to what
extent they represent all cases of MCI found in the gen-
eral population.Clinical signs and symptoms beyond those
cited in the official MCI criteria have also been used for
diagnosis,so there is likely to be some differences in case
identification between centers. While these studies
together suggest the high predictive validity of the concept
within a clinical setting,they are unable to provide us with
information on prevalence and incidence.To date,only a
small number of general population studies have been
conducted using MCI criteria,giving a range of prevalence
estimations from 3% to 19%.There are significant differ-
ences in sampling frames,cognitive tests,and drop-out due
to mortality and refusal between these studies;nonethe-
less, the majority of authors report rates of around 3%
when MCI criteria are strictly applied (Table II).
19-24
Subjects in three of the studies reporting higher rates
21-23
have received extensive clinical examinations as well as
cognitive testing,which may have led to the inclusion of
subjects on the basis of clinical criteria beyond those stip-
ulated in the definition of MCI.In three studies,
19-21 the
authors conclude in their discussion that the criteria are
too strict and a large number of subjects are subsequently
excluded who would be considered by clinicians as a
high-risk group.The principal problems with existing cri-
teria are reported to be in the areas of “subjective report-
ing of memory problems”and “intact activities of daily
living.”Modifying the criteria to allow for absence of sub-
jective memory problems and permitting changes in abil-
ity to perform activities of daily living was found by all
three studies to increase MCI prevalence to give rates
between 3% and 19%.
Both clinicians and epidemiologists have found the restric-
tion of MCI to an isolated memory deficit difficult to apply
in practice. Firstly, isolated memory dysfunction is rela-
tively rare;estimated at about 6% of all cases of subclini-
cal cognitive deficit,
25 at a clinical level it is very difficult to
define as even specific memory tests involve other cogni-
tive functions,such as language comprehension and atten-
tion.A recent working group of clinicians and epidemiol-
ogists working in the area of MCI met in Stockholm in
2003 and proposed new working criteria for MCI,
26 which
take into account the difficulties described above and pro-
vide clearer guidelines for clinical research.The new step-
wise algorithm, which also defines subtypes of MCI, is
based around the following three diagnostic features:
• Not normal,not demented (does not meet Diagnostic
and Statistical Manual of Mental Disorders, Fourth
Edition [DSM-IV] or International Classification of
Mental and Behavioral Disorders [ICD-10] criteria for
a dementia syndrome).
• Cognitive decline indicated by subject and/or informant
report and objective cognitive tests.
• Preserved basic activities of daily living with some min-
imal impairment in complex instrumental functions.
It is hoped that the application of these new diagnostic
guidelines will increase the comparability of clinical stud-
ies and thus produce more accurate estimates of disease
prevalence.
Little is currently known about incidence rates.Overall
population studies have shown somewhat lower conver-
sion rates from MCI to dementia than clinical studies,
which is not surprising given the more heterogeneous
nature of the cognitive deficit likely to be seen in this set-
ting.Three studies permit us to make estimates of inci-
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Table I. Rates of conversion to dementia for subjects with mild cognitive impairment (MCI) versus controls (where available).
Study n Time (years) Rate of conversion of  Rate of conversion of 
MCI to dementia (%) controls to dementia (%)
Petersen
7 et al 76 1 12 2
Johnson
11 et al 68 2 40
Tierney
12 et al 123 2 24
Flicker
13 et al 32 2 72 12
Grundman
14 et al 687 2 31 2
Bobinski
15 et al 12 3 50 0
Wolf
16 et al 41 3 20
McKelvey
17 et al 36 3 53
Morris
18 et al 277 9 100 7dence of 8,
19 26,
22 and 58
21 new cases per thousand sub-
jects annually.Yesavage et al
27 have attempted to model
incidence rates using a first-order Markovian Chain
Model to predict transition from normality to MCI based
on published prevalence,incidence,and conversion data.
They found a new case rate from normality to MCI start-
ing at 10 per 1000 at age 60 and increasing to reach 110
per 1000 at age 85.The proposed model probability esti-
mates are based on recent data on incidence,prevalence,
and conversion rates;however,these we have seen to be
divergent. The model also relies on age-specific AD
prevalence rates derived from a US study, which are
lower than those observed in European meta-analyses.
Analytical epidemiology of MCI
Numerous clinical and population studies have examined
risk factors for MCI conversion to dementia, but far
fewer the risk of transition to MCI from normal cogni-
tive functioning.Clinical case-control studies have pro-
vided cross-sectional information on differences between
MCI and normal aging with relation to brain structure
and function,and cognition.Compared with normal sub-
jects, MCI groups are seen above all to manifest left
medial temporal lobe atrophy and smaller medial tem-
poral lobe volumes.
16,28 Other studies have suggested that
white matter lesions,particularly in periventricular areas,
are associated with MCI.
29These findings suggest that the
clinical risks for conversion from normal to MCI are
principally related to degree of impairment along a con-
tinuum from normal aging-related changes to dementia.
Clinical cohort studies have provided very little informa-
tion on other health factors,or psychological,behavioral,
and environmental risks for transition to MCI.Two gen-
eral population epidemiological studies have attempted to
isolate clusters of risk factors by regression analysis based
on a wide range of clinical and sociodemographic factors.
Tervo et al
22 examined a range of demographic,vascular,
and genetic factors,and found the most significant risk fac-
tors to be age (odds ratio [OR] 1.08),apolipoprotein E4
(APOE-4) allele (OR 2.04),and medicated hypertension
(OR 1.86).High educational level was found to be a pro-
tective factor (OR 0.79) and the combination given the
highest risk was medicated hypertension plus APOE-4
(OR 3.92).Risk factors for MCI were also examined from
the multisite longitudinal Cardiovascular Health Study.
23,30
In this large study of 3608 subjects,which included neu-
ropsychological and neurological tests, general medical
examination,and magnetic resonance imaging (MRI),the
principal risk factors for MCI were found to be African-
American race,low educational level,Digit Symbol Test
score,cortical atrophy,MRI-identified infarcts,and depres-
sion.This study also examined MCI subtypes and found
risk factors for amnestic MCI to be infarcts,APOE-4 allele,
and low MMSE scores, while for multiple domain MCI
risk factors were MMSE and Digit Symbol Test scores.It
is difficult,however,to consider cognitive scores as a risk
factor for MCI,as they are part of the diagnostic algorithm
used to select cases. Data from a third study, the
Kungsholmen Project in Sweden,
31 also suggested that cer-
tain psychiatric symptoms may be predictive of MCI,
notably anxiety;however,this study did not use the usual
MCI criteria to identify cases.
Examining the various risk factors that have been iso-
lated for conversion from normal functioning to MCI,it
is possible to construct a hypothetical model of risk.
Figure 2 shows theoretical pathways (in black) to MCI
incorporating most of the known risk factors,which can
be seen to be largely those for dementia.There are,how-
ever, insufficient population data at present to permit
either a statistical calculation of transition probabilities
in relation to individual risk factors or a maximum like-
lihood calculation to assess the overall predictive value
of possible competing hypothetical general models.
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Table II. Prevalence rates for mild cognitive impairment (MCI) (and MCI revised criteria), annual incidence, and dementia conversion rates, where avail-
able. AD, Alzheimer’s disease.
Author Country n Prevalence Modified prevalence  Rate of conversion  Incidence
MCI (%) of MCI (%)  to AD (%)/years
Busse
19 et al Germany 1265 3.1 5.1 33/2.6 8/1000
Fisk
20 et al Canada 1790 1.03 3.02 46.7/5
Ritchie
21 et al France 833 3.2 19.3 11/2 58/1000
Tervo
22 et al Finland 806 8.8 26/1000
Lopez
23 et al USA 3608 19
Qiu
24 et al China 3910 2.4Interventional epidemiology
Finally,the role of interventional epidemiology is to sug-
gest possible intervention points within a hypothetical eti-
ological model to guide research into therapeutic inter-
vention. It appears increasingly likely that MCI, like
dementia,is the result of multiple lifetime insults in com-
bination with genetic vulnerability factors.The different
points at which intervention may be likely to reduce risk
have been added on to the theoretical model in blue in
Figure 2.A more complete clinical discussion of treatment
possibilities in MCI has been developed in the paper in
this issue by Gauthier.
32At the present time,there is clearly
no specific treatment for MCI,but it may be possible to
reduce overall risk by a number of simple strategies,which
do not in themselves have adverse consequences.These
include the management of cardiovascular and cere-
brovascular risk factors such as high blood pressure from
early adult life onward to reduce the risk of infarcts and
white matter lesion accumulation,controlling for depres-
sion,and the provision of adequate learning opportunities
from childhood.Other more active and contentious inter-
vention therapies for MCI, such as use of statins, anti-
inflammatory agents,the anticholinesterase therapies cur-
rently used in the treatment of dementia,and hormonal
replacement therapy,are being evaluated,but there is cur-
rently insufficient evidence for their widespread popula-
tion use in the prevention of MCI. It has been demon-
strated within a longitudinal population study that, by
entering MCI risk factors into a regression equation, a
probability statistic of developing dementia over a given
time period may be produced;this may assist clinicians in
the decision to undertake a therapeutic intervention that
has adverse side effects.
33
An avenue for future research in conjunction with the pro-
vision of cholinergic system therapies is to explore to what
extent the overall cholinergic burden may be reduced by
the readjustment of other medication being taken by an
elderly person. A very wide range of drugs have anti-
cholinergic effects,often unknown to the general practi-
tioner,and it is not known to what extent these may be a
common risk factor for MCI.The administration of anti-
cholinergic agents,such as scopolamine,in healthy young
subjects has been shown to produce very similar cognitive
deficits to MCI.
34 The range of drugs with known anti-
cholinergic effects is very large and includes such com-
monly prescribed drugs as the antihistamines, bron-
chodilators, antidepressants, antiulcer medication,
preanesthetics,and even some herbal teas.It has been esti-
mated that around a third of nursing home patients in the
USA take more than two anticholinergic drugs and 5%
more than five.
35 It is surprising that this important envi-
ronmental risk factor has not been taken into account in
epidemiological studies of environmental risk in MCI.
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Figure 2. Hypothetical etiological model of mild cognitive impairment (MCI) in black, and possible treatment or lifestyle intervention points in blue.
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MCI rates are likely to increase rapidly in parallel with the
extension of life expectancy at higher ages.Current esti-
mates of prevalence are limited by problems related to case
identification, but, in the light of several revisions of the
original definition,appear to be converging at around 5%
of the general population with around 15% per year going
on to develop dementia.Mortality risk is doubled in MCI
subjects.While the principal value of MCI remains the iden-
tification of persons in the first stages of neurodegenerative
disease,it also covers other forms of cognitive impairment
due to multiple causes,making the construction of mean-
ingful hypothetical etiological models extremely difficult.
The few studies of risk that have been carried out have
largely focused on known risk factors for dementia and
there is a clear need for longitudinal epidemiological stud-
ies that examine a wider range of genetic,biological,demo-
graphic,and environmental risk factors.Such studies are
extremely costly and difficult to justify for a health state that
is subclinical,poorly defined,often benign,and for which
no specific treatment is currently available.Epidemiologists
in this area should explore the possibility of grafting this
type of study on to existing longitudinal databases of pop-
ulation aging,which cover a much broader range of risk fac-
tors than those included in studies of dementia. ❏
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Deterioro cognitivo leve: una perspectiva epi-
demiológica
El deterioro cognitivo leve (DCL) se refiere a un
deterioro que se asume debido a procesos patoló-
gicos del sistema nervioso central, pero que inte-
ractúa con cambios relacionados al envejecimiento
normal. Estudios epidemiológicos realizados en
población general han permitido examinar formas
más heterogéneas de este trastorno que los estu-
dios clínicos y también han proporcionado las pri-
meras estimaciones de incidencia y prevalencia en
la población. Amplias diferencias en los procedi-
mientos de identificación de casos y métodos de
muestreo han conducido a divergencias considera-
bles en las cifras de prevalencia informadas, las cua-
les van desde el 1% al 29%. Se han propuesto
mejorías en la definición del DCL que han condu-
cido a un ajuste hacia arriba de las cifras de preva-
lencia en la mayoría de los estudios, llegando a
valores entre 5% y 29%. La incidencia se estima en
8 a 58 nuevos casos por mil personas por año, y la
probabilidad de conversión desde el DCL a la
demencia es estimada en alrededor del 15%. Los
principales factores de riesgo que se han identifi-
cado hasta la fecha para el DCL utilizando modelos
de regresión aplicados a los datos de población
general son edad, educación, raza, hipertensión en
tratamiento farmacológico, infartos, lesiones de la
sustancia blanca, depresión y presencia del alelo de
apolipoproteína E4 (APOE-4). Un modelo etiológico
derivado de estos estudios indica posibles puntos
de intervención para futuras estrategias terapéuti-
cas tanto para intervenciones clínicas como ambien-
tales. Existe, sin embargo, una clara necesidad de
estudios epidemiológicos que consideren un rango
mayor de factores de riesgo que los estudiados
hasta la fecha, los cuales se han centrado principal-
mente en los factores de riesgo conocidos para la
demencia.
Déficit cognitif léger : 
perspective épidémiologique
Le déficit cognitif léger (Mild Cognitive Impairment,
MCI) se rapporte à un déficit cognitif présumé dû à
des processus pathologiques du système nerveux cen-
tral, mais qui interagit avec les changements liés au
vieillissement normal. Des études épidémiologiques
effectuées dans la population générale ont permis
d’examiner des formes plus hétérogènes de ce trou-
ble que les études cliniques et de donner aussi des
estimations précoces de la prévalence et de l’inci-
dence dans la population. De grandes différences
dans les procédures d’identification des cas et les
méthodes d’échantillonnage ont conduit à de gran-
des divergences entre les taux de prévalence rap-
portés, qui allaient de 1 % à 29 %. Des améliorations
proposées pour définir le MCI ont abouti à un ajus-
tement à la hausse des taux de prévalence dans la
plupart des études, entre 5 % et 29 %. L’incidence est
estimée à 8 à 58 nouveaux cas pour 1 000 personnes
par an et la probabilité d’évolution du MCI vers la
démence autour de 15 %. Les principaux facteurs de
risque identifiés jusqu’ici pour le MCI en utilisant des
modèles de régression appliqués aux données de la
population générale sont l’âge, l’éducation, la race,
l’hypertension traitée, l’infarctus, les lésions de la
substance blanche, la dépression et l’allèle de l’apo-
lipoprotéine E4 (APOE-4). Un modèle étiologique issu
de ces études permet d’identifier les points d’inter-
vention possibles pour des stratégies thérapeutiques
futures, à la fois au niveau de l’intervention clinique
et de l’exposition environnementale. Des études épi-
démiologiques prenant en compte un plus large
échantillon de facteurs de risque que ceux étudiés à
ce jour, qui se sont principalement centrés sur les fac-
teurs de risque connus de la démence, sont néan-
moins clairement nécessaires.